Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
Preclinical findings demonstrate superior pharmacological activity, offering a differentiated mechanism-of-action to enhance anti-tumor immunity in advanced solid cancers
In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to conventional TIGIT antibodies. This novel, Fc-enhanced, bispecific antibody is differentiated from conventional TIGIT monoclonal antibodies by optimally targeting two critical immune checkpoint receptors in the same pathway, TIGIT and CD96. BMS-986442 (AGEN1777) leverages Agenus’ proprietary Fc-engineering platform to harness novel mechanisms of action that extend beyond the capabilities of conventional anti-TIGIT therapy. This innovative strategy could represent a promising approach to overcome the limitations of current anti-TIGIT therapies.
“Immune checkpoint blockade has emerged as a powerful strategy in enhancing anti-tumor immunity. However, conventional TIGIT antibodies have faced limitations with monotherapy activity in clinical settings,” said
Presentation Details:
Abstract Title: BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models
Abstract Number: 3915
Presenting Author:
Session: Immune Targets and Therapies
Presentation Session Date and Time:
Data presented at the conference will be available to view in the publications section of the
About BMS-986442 (AGEN1777)
BMS-986442 (AGEN1777) is being developed in partnership between
About
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding a partnered BMS-986442 program, expected timelines, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306083511/en/
Investors
917-362-1370
investor@agenusbio.com
Media
781-674-4784
communications@agenusbio.com
Source: